Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Receivables (2016 - 2025)

Historic Receivables for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $78.2 million.

  • Mimedx's Receivables rose 4470.85% to $78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.2 million, marking a year-over-year increase of 4470.85%. This contributed to the annual value of $59.0 million for FY2024, which is 944.66% up from last year.
  • Latest data reveals that Mimedx reported Receivables of $78.2 million as of Q3 2025, which was up 4470.85% from $69.2 million recorded in Q2 2025.
  • Mimedx's Receivables' 5-year high stood at $78.2 million during Q3 2025, with a 5-year trough of $36.1 million in Q1 2021.
  • Its 5-year average for Receivables is $50.7 million, with a median of $51.2 million in 2023.
  • As far as peak fluctuations go, Mimedx's Receivables soared by 430.23% in 2022, and later soared by 4470.85% in 2025.
  • Over the past 5 years, Mimedx's Receivables (Quarter) stood at $40.4 million in 2021, then increased by 16.14% to $46.9 million in 2022, then increased by 14.94% to $53.9 million in 2023, then increased by 9.45% to $59.0 million in 2024, then surged by 32.61% to $78.2 million in 2025.
  • Its Receivables stands at $78.2 million for Q3 2025, versus $69.2 million for Q2 2025 and $62.3 million for Q1 2025.